2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 163

The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population
Abstract Number: 892

The Functional PTPN22 Variant R620W Is Strongly Associated With Giant Cell Artetitis Predisposition
Abstract Number: 3

The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Abstract Number: 187

The Health and Economic Consequences Of Delay In Starting Disease-Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Abstract Number: 2708

The Hedgehog Transcription Factor Gli-2 Is a Novel Downstream Mediator Of The Pro-Fibrotic Effects Of Transforming Growth Factor-Beta
Abstract Number: 2221

The Histamine H₄ Receptor Drives Inflammation In Preclinical Models Of Arthritis
Abstract Number: 2111

The Impact Of Centralized Pain On Long-Term Analgesic Response To Lower Extremity Joint Arthroplasty: A Prospective, Observational Cohort Study
Abstract Number: 1020

The Impact Of Diagnostic Decision Rules Used In Administrative Healthcare Databases On The Frequency Of Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 495

The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Abstract Number: 1333

The Impact Of Menopause In Rheumatoid Arthritis Activity
Abstract Number: 2878

The Importance Of Germinal Center-Like Structures In Primary Sjögren’s Syndrome Salivary Glands Beyond Lymphoma Risk
Abstract Number: 48

The In Vivo Role Of Bone Specific EphB4 Receptor Overexpression In Osteoarthritic Synovial Membrane
Abstract Number: 2403

The Incidence Of Factor V Leiden A1691G, Methylene Tetrahydrofolate Reductase C677T, and Prothrombin G20210A Mutation In Patients With Rheumatoid Arthritis
Abstract Number: 1036

The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study
Abstract Number: 1423

The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].